Basem Mishriky, MD, FACP, ABOM Diplomate

Obesity Medicine Specialist and fellowship-trained Diabetologist. Tweets are updates in the diabetes field and are not endorsement/medical advise.

[Basem Mishriky, MD, FACP, ABOM Diplomate @BasemMishriky]

Honored to be at #ADA2022 to present retrospective study evaluating #hHF in individuals who identify as #AA vs #White with #T2DM on #empagliflozin. Link to poster below.

https://t.co/toltf1MeeK

@ADA_DiabetesPro #diabetes #retrospective @GoggleDocs @MedscapeEndo

[Basem Mishriky, MD, FACP, ABOM Diplomate @BasemMishriky]

FDA Approves First Once-Weekly Insulin for Type 2 Diabetes https://t.co/PjfWJ1qIIq

[Prof Kamlesh Khunti @kamleshkhunti]

🚨 Nicotine is a cardiovascular toxin — regardless of delivery system.

A new expert consensus outlines 12 evidence-based messages showing that cigarettes, e-cigs, heated tobacco & nicotine pouches all harm vascular and metabolic health 🫀⚠️

👶 Alarmingly, flavoured products and aggressive marketing are driving a paediatric addiction crisis, fuelled by the myth of “safer nicotine.”

📜 The paper calls for comprehensive regulation: advertising bans, flavour restrictions & indoor-use prohibitions-across all nicotine products.

https://t.co/CikJyAB3zj

@DHSCgovuk

[Basem Mishriky, MD, FACP, ABOM Diplomate @BasemMishriky]

https://t.co/2bijedQ7Vb

[Basem Mishriky, MD, FACP, ABOM Diplomate @BasemMishriky]

https://t.co/rp4plGC8dJ

[Basem Mishriky, MD, FACP, ABOM Diplomate @BasemMishriky]

Finerenone reduces albuminuria in adults with type 1 diabetes https://t.co/NHZaK5Mpsk

[Basem Mishriky, MD, FACP, ABOM Diplomate @BasemMishriky]

Rybelsus approved for CVD prevention in adults with diabetes https://t.co/WaJCcuw3oG

[Basem Mishriky, MD, FACP, ABOM Diplomate @BasemMishriky]

No retinopathy risk found with GLP-1 drugs in new study https://t.co/YOFVHgnsVY

[GoggleDocs @GoggleDocs]

❗️A trial we have kept an eye on announces primary outcome met ❗️

FINE-ONE Finerenone in T1DM potentially provides an opportunity to address renal risk (maybe more) in this population with unmet need

https://t.co/1Hb6fsg5Dh

@AmarPut @drpatrickholmes @kamleshkhunti

[Dr Alo, DO, FACC @MohammedAlo]

Trizepatide Vs Semaglutide & CVD Risk Reduction

1️⃣ Baseline risk: 10-year CVD risk averaged 9.3% before treatment.

2️⃣ Risk reduction: Tirzepatide lowered absolute risk by 2.4% vs 1.4% with semaglutide.

3️⃣ Impact: Could prevent 2M CVD events over 10 years vs 1.15M with semaglutide.

@DrNadolsky @DrKarlNadolsky @drmatthewnagra @NutritionMadeS3 @MichaelAlbertMD @BevTchangMD

https://t.co/QQrNsYZxNM

[Michael Albert, MD @MichaelAlbertMD]

🚨 Top-Line Results: Mazdutide vs. Semaglutide (1 mg) 🚨
- - -
The first-ever head-to-head Phase 3 trial of a GCG/GLP-1 dual agonist vs. semaglutide—DREAMS-3—just released its topline data in adults with type 2 diabetes and obesity.

At 32 weeks:
🔥 HbA1c <7% + ≥10% weight loss: 48% (Mazdutide) vs. 21% (Semaglutide 1 mg)
📉 Mean HbA1c reduction: −2.03% vs. −1.84%
⚖️ Mean weight loss: 10.3% vs. 6.0%
✅ No new safety signals—GI side effects remained the most common

💡 Mazdutide is an oxyntomodulin analogue that activates both GLP-1 and glucagon receptors, potentially boosting energy expenditure and hepatic fat metabolism beyond classic incretin effects.

🌏 Developed by Innovent Biologics (under license from Eli Lilly), Mazdutide is already approved in China for both chronic weight management and type 2 diabetes—the first dual GCG/GLP-1 therapy with regulatory clearance.

👀 Why it matters:
NuSH polyagonists may redefine metabolic care—offering greater reductions in glucose, weight, and liver fat than GLP-1–only therapies.
🔗https://t.co/T6arJA6nH5

[Daniel J Drucker @DanielJDrucker]

Once again.....Real world data #T2D reveals GLP-1RAs and DPP-4is were associated with a small increase in risk of biliary disease, but not of acute pancreatitis compared with SGLT2is https://t.co/0hHDolOJWN

[Daniel J Drucker @DanielJDrucker]

Turns out that if you lose weight you feel better https://t.co/cN7pRX5ISf

[Prof Kamlesh Khunti @kamleshkhunti]

🥦 Plant-based diets, lifestyle & dementia risk

📊 UK Biobank (n=71,648; ≥55 yrs; 12.5 yr follow-up):

• High-quality plant-based diet (hPDI)↓ dementia risk 61% (HR 0.39)

• Unhealthy plant diet ↑ risk 3.2x (HR 3.24)

👉 Not all plant-based diets are equal — quality and overall lifestyle matter for brain health.

#Dementia #Nutrition #CardioMetabolic #PlantBased #LifestyleMedicine #PublicHealth

https://t.co/x9NtAuYvV6

@mmamas1973 & @docwas just saying 😜

[Daniel J Drucker @DanielJDrucker]

In people with HIV, Semaglutide for 32 weeks may have a beneficial impact on visuospatial cognitive function in PWH, associated with its effect on inflammation https://t.co/rX6wnQvGN2

[Prof Kamlesh Khunti @kamleshkhunti]

🩺 SGLT2 inhibitors for primary prevention in T2 Diabetes (T2D)

Can SGLT2i reduce first-time cardiovascular (CV) events in people without prior heart disease? 🇹🇼

New nationwide cohort (Taiwan)

📊 Mean follow-up ≈ 2.8 years

❤️ In patients with hypertension
SGLT2i vs DPP-4i ↓ risk of:
· 🧠Stroke   HR 0.56
· ❤️Coronary artery disease HR 0.80
· 💔Heart failure HR 0.31
· ⚡ MACE    HR 0.62

💓 In patients without hypertension
SGLT2i ↓ risk of:
· 💫 Atrial fibrillation HR 0.48

✅ Takeaway:
Even in people with T2D without established CVD, SGLT2 inhibitors show:
· Broad protection across major CV outcomes

· Potential role in primary prevention—especially when hypertension is present

#Diabetes #Cardiology #SGLT2i #Prevention #T2D #HeartHealth

https://t.co/8OLLXEF23M

@mmamas1973

[Daniel J Drucker @DanielJDrucker]

The P3 Retatrutide TRIUMPH trials #obesity https://t.co/3WsNqkuKFk

[Daniel J Drucker @DanielJDrucker]

Inflammation is a key driver of the pathophysiology of cardiometabolic disorders #obesity #T2D and new metabolic medicines based on GLP-1 action exert their magic in part by reducing inflammation. A new review from Professor Donath summarizes the field https://t.co/7mDWLvqvyw

[Dr Alo, DO, FACC @MohammedAlo]

American Association of Clinical Endocrinology Consensus Statement On Obesity

Congratulations @DrKarlNadolsky

@DrNadolsky @NutritionMadeS3 @drmatthewnagra @BevTchangMD @MichaelMindrum @MichaelAlbertMD

https://t.co/9OB19llyx5

[Daniel J Drucker @DanielJDrucker]

Are some GLP-1 medicines more cardioprotective than others? #easd25 A new real world study using US Medicare data https://t.co/dh0F8R573g

[Daniel J Drucker @DanielJDrucker]

Worth a read for context on the "lean mass muscle loss" #obesity GLP-1 medicine debate. Keep an eye on muscle function and health, diet quality and resistance #exercise and not just the DXA scan @SA_Diabetes @MolMetab #weightloss https://t.co/W4fx6PqplL